Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care
Executive Summary
In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.